ANXA1, His, Cynomolgus
ANXA1, His, Cynomolgus

The purity of ANXA1, His, Cynomolgus is greater than 95% as determined by SEC-HPLC.

ANXA1, His, Cynomolgus

ANXA1, His, Cynomolgus on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

ANXA1, His, Cynomolgus

Atherosclerosis, characterized by the formation of fat-laden plaques, is a chronic inflammatory disease. ABCA1 promotes cholesterol efflux, reduces cellular cholesterol accumulation, and regulates anti-inflammatory activities in an apoA-I- or ANXA1-dependent manner. The latter activity occurs by mediating the efflux of ANXA1, which plays a critical role in anti-inflammatory effects, cholesterol transport, exosome and microparticle secretion, and apoptotic cell clearance.
Z04733
¥80,213.00

Ask us a question
Product Introduction
Species Cynomolgus
Protein Construction
ANXA1 (Ala2-Asn346)
Accession # XP_005581995.1		 His
N-term C-term
Purity > 95% as determined by Bis­Tris PAGE 
> 95% as determined by HPLC
Endotoxin Level Less than 1EU per μg by the LAL method.
Expression System E.coli
Theoretical Molecular Weight 39.69 kDa
Apparent Molecular Weight The protein has a predicted MW of 39.69 kDa same as Bis-Tris PAGE result.
Formulation Lyophilized from 0.22μm filtered solution in PBS (pH 7.4).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles.

Examples
  • ANXA1, His, Cynomolgus
    • ANXA1, His, Cynomolgus

    The purity of ANXA1, His, Cynomolgus is greater than 95% as determined by SEC-HPLC.

  • ANXA1, His, Cynomolgus
    • ANXA1, His, Cynomolgus

    ANXA1, His, Cynomolgus on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.


Background
Target Background Atherosclerosis, characterized by the formation of fat-laden plaques, is a chronic inflammatory disease. ABCA1 promotes cholesterol efflux, reduces cellular cholesterol accumulation, and regulates anti-inflammatory activities in an apoA-I- or ANXA1-dependent manner. The latter activity occurs by mediating the efflux of ANXA1, which plays a critical role in anti-inflammatory effects, cholesterol transport, exosome and microparticle secretion, and apoptotic cell clearance.
Synonyms Annexin I; Calpactin II; Calpactin-2; Chromobindin-9; Lipocortin I; p35; ANX1; LPC1; Annexin A1; Annexin-1; ANXA1

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.